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Quantification of FDG-PET/CT with delayed
imaging in patients with newly diagnosed
recurrent breast cancer
Christina Baun1* , Kirsten Falch1, Oke Gerke1,2, Jeanette Hansen1, Tram Nguyen1, Abass Alavi3,
Poul-Flemming Høilund-Carlsen1 and Malene G. Hildebrandt1
Abstract
Background: Several studies have shown the advantage of delayed-time-point imaging with 18F-FDG-PET/CT to
distinguish malignant from benign uptake. This may be relevant in cancer diseases with low metabolism, such as
breast cancer. We aimed at examining the change in SUV from 1 h (1h) to 3 h (3h) time-point imaging in local and
distant lesions in patients with recurrent breast cancer. Furthermore, we investigated the effect of partial volume
correction in the different types of metastases, using semi-automatic quantitative software (ROVER™).
Methods: One-hundred and two patients with suspected breast cancer recurrence underwent whole-body PET/CT
scans 1h and 3h after FDG injection. Semi-quantitative standardised uptake values (SUVmax, SUVmean) and partial
volume corrected SUVmean (cSUVmean), were estimated in malignant lesions, and as reference in healthy liver tissue.
The change in quantitative measures from 1h to 3h was calculated, and SUVmean was compared to cSUVmean.
Metastases were verified by biopsy.
Results: Of the 102 included patients, 41 had verified recurrent disease with in median 15 lesions (range 1-70) amounting
to a total of 337 malignant lesions included in the analysis. SUVmax of malignant lesions increased from 6.4 ± 3.4 [0.9-19.7]
(mean ± SD, min and max) at 1h to 8.1 ± 4.4 [0.7-29.7] at 3h. SUVmax in breast, lung, lymph node and bone lesions
increased significantly (p < 0.0001) between 1h and 3h by on average 25, 40, 33, and 27%, respectively. A similar pattern
was observed with (uncorrected) SUVmean. Partial volume correction increased SUVmean significantly, by 63 and 71% at
1h and 3h imaging, respectively. The highest impact was in breast lesions at 3h, where cSUVmean increased by 87%
compared to SUVmean.
Conclusion: SUVs increased from 1h to 3h in malignant lesions, SUVs of distant recurrence were in general about twice
as high as those of local recurrence. Partial volume correction caused significant increases in these values. However, it is
questionable, if these relatively modest quantitative advances of 3h imaging are sufficient to warrant delayed imaging in
this patient group.
Trial registration: ClinicalTrails.gov NCT01552655. Registered 28 February 2012, partly retrospectively registered.
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Background
Breast cancer is the most frequent cancer among women
in western countries, and up to 30% of patients are likely
to develop recurrence [1, 2]. 18F-fluoro-deoxy-glucose
positron emission tomography/computed tomography
(FDG-PET/CT) is useful in the diagnosis, staging and
therapeutic follow-up of patients with recurrent breast
cancer, and is especially better than conventional im-
aging at detecting distant metastases [3–5].
FDG is not specific for malignancy; however, recent
studies have shown the advantage of delayed or dual-
time imaging with FDG-PET to distinguish malignant
from benign uptake [6–8]. The underlying rationale is
that malignant cells have more glucose transporters and
hexokinases and less glucose-6-phosphatase (G6Pase),
which leads to FDG accumulation over time compared
to benign cells [9, 10]. Delayed scan time-points may
thus improve the image quality due the greater differ-
ence between tumour and background levels [11–14].
This may be relevant in cancer diseases with low metab-
olism, such as breast cancer.
Only a few studies have examined the use of delayed
time-point imaging (DTPI) in whole-body FDG-PET/CT
to show the FDG accumulation over time associated
with distant metastases [15–17]. The literature suggests
that more prospective studies are needed to provide a
better understanding of the use of DTPI in detecting re-
current breast cancer [6, 18, 19]. Analysis of PET data is
often performed semi-quantitatively by measuring stan-
dardised uptake values (SUV) in lesions suspected of
malignancy [20–22]. SUV has been referred to correlate
well with histological and biological tumour characteris-
tics, and can be an important tool in the diagnostic re-
port for breast cancer patients [23–25]. SUV is strongly
affected by the partial volume effect (PVE), however,
which can cause a significant underestimation of the le-
sion uptake level [26–28]. Although methods for partial
volume correction (PVC) have been developed to over-
come this limitation, no method has yet found its place
in daily clinical practice. Further evidence is needed to
state the usefulness and feasibility of these software
methods [29–32].
We aimed at examining the value of whole-body FDG-
PET/CT performed at 3 h (3h) compared to the stand-
ard imaging time-point at 1 h (1h), in patients suspected
of recurrent breast cancer, using quantitative software
that included PVC.
Our objectives were to investigate i) the change in
standardised uptake values from early (1h) to delayed
(3h) time-point imaging in local and distant lesions,
by measuring SUVmax, SUVmean and correcting
SUVmean for PVE (cSUVmean), and ii) the effect of
PVC by comparing SUVmean and cSUVmean at both
time-points.
Methods
One-hundred and two women with suspected breast can-
cer recurrence or with verified local recurrence and poten-
tial distant disease were enrolled in the study. The
patients were part of a larger prospective accuracy study
comparing FDG-PET/CT to conventional imaging in de-
tecting recurrent breast cancer [33]. The prospective study
was conducted at the PET centre, Odense University Hos-
pital, Denmark, from December 2011 to September 2014.
Exclusion criteria were history of other malignancies, age
< 18 years, pregnancy or breastfeeding, diabetes mellitus,
or considered unable to cooperate. For further methodo-
logical details we refer to our recent publication [33].
FDG-pet/CT
Patients were required to fast for at least 6 h before the
FDG-PET/CT scan. A maximum blood glucose level of
144 mg/dL was allowed prior to intravenous injection of
4 MBq/kg FDG. Whole-body FDG-PET/CT scans were
performed 1h and 3h after FDG injection on a General
Electric Discovery STE or Discovery RX system (GE
Healthcare, Milwaukee, USA). A low-dose CT scan
(140 kV, 30-110 mA; Auto- and Smart mA) was per-
formed followed by a 3D PET scan. Acquisition time was
of 2.5 min/frame for the 1h scan and 3.5 min/frame for
the 3h scan, for patients with a normal body mass index
(BMI) between 18.5 kg/m2 and 24.9 kg/m2. If BMI was
lower or higher, the scan time was adjusted according to
BMI and either decreased or increased by ½ min/frame,
respectively. Images were reconstructed iteratively using
an ordered subset expectation maximization (OSEM)
algorithm, with 2 iterations, and 21 or 28 subsets, a slice
thickness of 3.3 mm and matrix size of 128 × 128 (pixel
size of 5.47mm2) with CT-based attenuation correction
and 5 mm Gaussian post-filtering.
Reference standard
Suspected recurrence was verified by biopsy. If biopsy was
not possible, a composite reference standard comprising
all available imaging procedures (MRI, CT, PET/CT, bone
scan, ultrasound, x-ray and mammography) and/or clin-
ical follow-up data over 6 months was used as gold stand-
ard, using the patients’ medical files as necessary. In
patients with multiple lesions, it was not possible to obtain
a biopsy from all lesions for ethical reasons. The patients
were categorised into groups of ‘local recurrence’ or ‘dis-
tant recurrence’ based on reference standard and in ac-
cordance with treatment decision.
Image interpretation
The scans were visually interpreted by an experienced
nuclear medicine physician using the General Electric
acquisition workstation. The 1h and 3h images were
read independently. Each lesion was described with
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anatomic site and exact image number for further semi-
quantitative analysis. The lesions were divided into seven
subgroups according to lesion site: cerebrum, lung, liver,
breast, lymph node, bone and ‘other’ (subcutaneous and
muscle metastasis).
Semi-quantitative analysis
Semi-quantitative analysis of the malignant lesions was
retrospectively performed using dedicated image analysis
software (ROVER™, ABX, Radeberg, Germany). This
software provides semi-automatic image segmentation
with a model-free method for PVE correction of SUV-
mean values. The software performs lesion delineation
within a user-defined 3D mask using fixed, peak-based
thresholding to delineate the lesion region-of-interest
(ROI), which represents the metabolic active tumour
volume (MTV). In the following step, ROVER performs
PVC using an algorithm that defines a spill-out region of
the lesion ROI from which a background corrected esti-
mate of the spill-out region is calculated and used to
perform PVC of SUVmean resulting in cSUVmean.
Further details regarding software algorithms are ex-
plained by Hofheinz et al. [32, 34]. The ROVER software
was used in standard mode with a threshold setting of
40% of maximum 3D mask value, including a minimum
ROI volume of 1cm3 and excluding ROI intersection.
SUV values were normalised to body weight. Manually
placement of 3D masks was performed after visual
identification of the lesion by the interpreting physician.
Masks were placed 2-4 pixels beyond the visual margin
of each lesion, and ROVER automatically delineated the
lesion ROI and performed PVC. It automatically calcu-
lated ROI values of SUVmax, SUVmean, cSUVmean and
MTV. Separate 3D masks were used for the same lesions
in the 1h and 3h scans. If a lesion had no discernible
FDG uptake in the early images, the 3D mask was placed
as close as possible to the assumed origin based on ana-
tomic orientation. A reference measurement in healthy
liver tissue was obtained in all patients at both time-
points. This was performed by drawing a mask of a
proximately 36 cm3 in the upper right lobe of healthy
liver tissue, avoiding malignancies and organ boundaries.
Potential metastatic lesions without FDG-uptake would
not be registered for analysis. The difference in SUV-
max, SUVmean, cSUVmean, and MTV between the two
time-points were calculated as ΔSUV=SUV3h - SUV1h,
and ΔMTV=MTV3h - MTV1h.
Statistical analysis
Descriptive statistics were performed for demographic
variables and scanning parameters. The semi-
quantitative analysis parameters from the 1h and 3h
scans were expressed as mean ± standard deviation (SD)
and range. Boxplots were used for graphical display of
the data. The differences in SUVs between the two time-
points as well as the difference between SUVmean and
cSUVmean measurements at each time-point were esti-
mated together with 95% confidence intervals (CI) and
p-values that were derived from univariate linear regres-
sion models using robust standard errors to allow for
intragroup correlation (i.e. multiple lesions in the same
patient). Subgroup analyses were conducted by recur-
rence category (distant versus local recurrence) and
lesion site, where healthy liver tissue was used as the ref-
erence category. Analyses were supplemented by relative
changes of mean values in groups, e.g. (mean value of 3h
measurements – mean value of 1h measurements)/
(mean value of 1h measurements)*100%.
Statistical tests were two-sided with a significance level
of 5%. Analyses were conducted with Stata/MP 14.0
(StataCorp LP, College Station, Texas 77845, USA).
Results
Of the 102 patients who initially agreed to participate in
the study one patient changed her mind before FDG-PET/
CT, another was excluded due to a previous biopsy-
verified bone metastasis, and a third patient did not
complete the 3h scan, leaving 99 women available for ana-
lysis. Forty-one of these (41.4%) were diagnosed with re-
current breast cancer, with a total of 337 malignant lesions
(mean 15, range 1-70) available for analysis. The patient
and scanning characteristics are given in Table 1.
Nineteen patients had local recurrence comprising 21
lesions, and 22 patients had distant disease with 316 le-
sions. All patients had at least one biopsy to verify recur-
rence. Biopsies were primarily taken from breast lesions.
For patients with recurrent disease and multiple distant
metastases, only one distant lesion was verified by biopsy
due to ethical aspect. All remaining metastatic lesions
were verified by the composite reference standard, as
Table 1 Patient and scanning characteristics of 1h and 3h FDG-
PET/CT, performed in the 41 patients with recurrent breast cancer
Patient characteristics Mean ± SD, range
Patient age (years) 62 ± 4.2 [57;74]
Body mass index 27 ± 7.1 [22;32]
Blood glucose level (mmol/L) 5.4 ± 1.0 [3.8;7.7]
Years since treatment of primary
breast cancer
6 ± 8.2 [0;30]
Scanning characteristics
Dose (MBq) 281 ± 56.0 [208;401]
Time (min) between injection
and early scan (1h)
62 ± 6.0 [53;80]
Time (min) between injection
and late scan (3h)
180 ± 6.0 [170;200]
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described in the method section. Distribution of lesions
and biopsies are shown in Table 2.
Local vs. distant recurrence
The overall SUV measurements for all 41 patients in-
creased, on average, significantly between 1h and 3h, i.e.,
SUVmax by 1.8 (+ 28% increase), SUVmean by 1.1 (+ 28%),
and cSUVmean by 2.3 (+ 35%). Overall, MTV decreased
significantly over time, particularly for patients with distant
recurrence in whom it decreased by 16%, shown in Table 3.
The values of distant recurrence were in general about
twice as high as those of local recurrence, but the rela-
tive average increase was the same for the two groups.
In both groups, the relative increase in cSUVmean
(35-36%) was greater than the increase in SUVmean and
SUVmax (25-28%). Despite these average tendencies,
some lesions showed reduced SUVmax values at 3h, i.e.,
8 lesions (38%) in patients with local recurrence and 31
lesions (10%) in patients with distant recurrence.
Changes by lesion subgroup
Except for and the lesion group ‘other’, all subgroups
showed a significant increase in SUVmax and SUV-
mean over time, compared to the reference measure-
ments in healthy liver tissue (Fig. 1). Lymph node
metastases showed the highest absolute increase in
SUVmax by 2.1 [1.4-2.8] (mean, 95% CI) (+ 33%),
SUVmean by 1.5 [0.1-0.7] (+ 36%) and cSUVmean by 3.
2 [2.6-3.2] (+ 47%). The highest relative increase in
SUVmax, SUVmean and cSUVmean over time was seen
for lung metastases at 40, 44 and 52%, respectively.
Breast lesions showed the smallest absolute increase
from 1h to 3h in SUVmax, SUVmean and cSUVmean
at 0.7 [0.2-1.1] (+ 25%), 0.4 [0.1-0.7] (+ 24%) and 1.2 [0.
4-1.9] (+ 42%). Liver lesions showed the lowest relative
increase in SUVmax, SUVmean and, cSUVmean of 18,
16 and 18% respectively. Reference tissue in healthy
liver showed a significant average decrease in SUVmax
by 11 and 20%, respectively.
Despite the overall increase in SUV for lesion sub-
groups, some lesions showed reduced SUV over time, i.
e., 1 (4%) in the lung, 1 (14%) in liver, 11 (41%) in breast,
3 (6%) in lymph nodes, 22 (7%) in bone and 1 (10%) of
the ‘other’ lesions. The percentages of lesions with de-
creased values between the two time-points were the
same for SUVmax, SUVmean and cSUVmean. Due to
only one cerebral metastasis, this lesion group was not
considered representative and is not commented upon
in the results or discussion sections. MTV decreased, on
average, significantly for all lesion subgroups between 1h
and 3h; however, for liver lesions and ‘other’ lesions the
decrease was not significant. The greatest decrease (of
43%) in MTV was seen in breast lesions. For details re-
garding lesion subgroups, see supplementary data given
in Additional file 1.
Partial volume correction
For all lesions as a whole, cSUVmean was significantly
higher than SUVmean at both 1h (mean difference of 2.
5 equal to 63%) and 3h (3.6 equal to 71%) except lesions
‘other’ and liver metastases at 1h, which was insignifi-
cantly higher (Table 4). For patients with local recur-
rence cSUVmean was 70% higher than SUVmean at 1h
and 84% at 3h and for distant recurrence 63% higher at
1h and 71% at 3h, see Table 4.
At lesion site the largest difference was at 3h for breast
lesions, where cSUVmean was 87% higher than SUV-
mean. The smallest difference was at 1h for liver lesions,
in which cSUVmean was 39% higher than SUVmean
(Table 4). Generally, cSUVmean varied more than SUV-
mean in all lesion sites (Fig. 2). Further details regard-
ing lesion subgroups, see supplementary data given in
Additional file 1.
Discussion
This study of malignant lesions in 41 out of 99 analysed
patients with breast cancer recurrence showed signifi-
cant overall increase in uptake of FDG between 1h and
3h scans. The values of distant recurrence were in gen-
eral about twice as high as those of local recurrence, but
the relative increase was the same for the two groups
(Table 3). Lymph node metastases showed the highest
absolute increase in SUV between the two time-points,
whereas lung metastases displayed the highest relative
increase. PVC led to higher uptake estimates, especially
for patients with local recurrence and for breast lesions
at the 3h scan (Table 4 and Fig. 2). We found decreased
SUV over time in reference tissue (healthy liver) as ex-
pected and hence an increased tumour-to-background
ratio for delayed imaging.
Table 2 Distribution of 337 malignant lesions in 41 recurrent
breast cancer patients, according to recurrence status and lesion
site. Lesion group ‘other’ consisted of subcutaneous and muscle
metastases
Sites of
recurrence
Number
of patients
Number
of lesions
Number
of biopsies
Local recurrence 19 21 19
Distant recurrence 22 316 22
Cerebrum 1 1 (0.3%) 1
Lung 6 25 (7.4%) 1
Liver 4 7 (2.1%) 3
Breast 23 27 (8.0%) 21
Lymph node 13 54 (16.0%) 8
Bone 18 213 (63.2%) 7
Other 2 10 (3.0%) 5
Baun et al. BMC Medical Imaging  (2018) 18:11 Page 4 of 10
Table 3 Standard uptake values (SUVmax, SUVmean, partial volume corrected SUVmean (cSUVmean) and MTV of malignant lesions
at 1h and 3h (mean ± SD, min and max), and the change over time (ΔSUV with 95% CI) by patient recurrence status. ΔSUV% and
ΔMTV% were calculated by using mean values of 1h and 3h groups. P-values refer to the hypothesis test that the mean difference
of the paired observations at 1h and 3h is equal to 0
1h 3h ΔSUV (3h-1h) p-value ΔSUV%
All 41 patients with recurrence (337 lesions)
SUVmax 6.4 ± 3.4
[0.9-19.7]
8.1 ± 4.4
[0.7-29.7]
1.8
[1.5 to 2.1]
< 0.0001 28
SUVmean 4.0 ± 2.0
[0.5-11.3]
5.1 ± 2.6
[0.4-16.5]
1.1
[1.0 to 1.3]
< 0.0001 28
cSUVmean 6.5 ± 3.5
[0.7-20.8]
8.8 ± 4.7
[0.5-30.9]
2.3
[1.9 to 2.6]
< 0.0001 35
MTV (cc) 12.5 ± 42.4
[0.3-562]
10.4 ± 39.9
[0.2-565.5]
−2.1
[− 3.1 to − 1.0]
< 0.0001 − 17
19 patients with local recurrence (21 lesions)
SUVmax 3.0 ± 1.9
[0.9-8.7]
3.8 ± 3.0
[0.7-12.3]
0.8
[0.2 to 1.4]
0.006 27
SUVmean 1.9 ± 1.3
[0.5-5.9]
2.4 ± 2.0
[0.4-8.6]
0.5
[0.08 to 0.9]
0.022 25
cSUVmean 3.2 ± 2.4
[0.7-8.9]
4.4 ± 3.9
[0.5-14.4]
1.2
[0.3 to 2.1]
0.014 36
MTV (cc) 8.4 ± 10.3
[0.3-33.3]
5.7 ± 5.5
[0.2-22.3]
−2.8
[−6.2 to 0.7]
0.11 −33
22 patients with distant recurrence (316 lesions)
SUVmax 6.6 ± 3.3
[1.2-19.7]
8.4 ± 4.4
[1.2-29.7]
1.8
[1.5 to 2.2]
< 0.0001 28
SUVmean 4.1 ± 2.0
[0.8-11.3]
5.3 ± 2.6
[0.6-16.5]
1.2
[1.0 to 1.4]
< 0.0001 28
cSUVmean 6.7 ± 3.5
[0.8-20.8]
9.1 ± 4.6
[0.8-30.9]
2.3
[2.0 to 2.7]
< 0.0001 35
MTV (cc) 12.8 ± 43.7
[0.4-562.0]
10.7 ± 41.1
[0.2-565.5]
−2.1
[−3.2 to −0.9]
0.001 −16
Fig. 1 Boxplots of SUVmax, at 1h and 3h imaging time-point, for the 337 malignant lesions according to the different subgroups and reference
tissue (healthy liver) in 41 patients with recurrent breast cancer. Due to only one cerebral lesion, data are not shown for this group
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Although our study, in line with previous literature,
demonstrated an increased tumour-to-background ratio
in delayed images, the diagnostic accuracy at patient
level did not improve in our overall prospective accuracy
study [33]. The clinical usefulness of delayed imaging in
this category of patients may thus be limited. Further-
more, it is our experience that DTPI caused planning
challenges in daily workflow and patient discomfort due
to a longer fasting period.
Change in SUV from early to late time-point imaging
Patients with local recurrence had in general lower SUV-
max and SUVmean measurements compared to the
group with distant recurrence at both time-points. This
Table 4 Difference between SUVmean and cSUVmean for 1h and 3h measurements for all lesions according to recurrent status and
lesion subgroups (mean and 95% CI). Percentage difference was calculated by using mean values of cSUVmean and SUVmean
groups for 1h and 3h. P-values refer to the hypothesis test that the mean difference of the paired observations at each time-point
for SUVmean and cSUVmean is equal to 0
Group Difference 1h
(cSUVmean-SUVmean)
p-value % diff Difference 3h
(cSUVmean-SUVmean)
p-value % diff
All lesions
(337 lesions)
2.51
[2.14 – 2.88]
< 0.0001 63 3.64
[3.22 – 4.06]
< 0.0001 71
Local recurrence
(21 lesions)
1.32
[0.74 – 1.91]
< 0.0001 70 2.02
[1.07 - 2.98]
< 0.0001 84
Distant recurrence
(316 lesions)
2.59
[2.21 - 2.98]
< 0.0001 63 3.75
[3.32 - 4.18]
< 0.0001 71
Lung
(25 lesions)
1.88
[0.48 – 3.27]
0.018 60 3.09
[1.28 - 4.91]
0.007 68
Liver
(7 lesions)
2.17
[−0.80 – 5.14]
0.103 39 2.67
[0.91 - 4.44]
0.017 41
Breast
(27 lesions)
1.09
[0.59 - 1.60]
< 0.0001 63 1.86
[1.06 - 2.66]
< 0.0001 87
Lymph node
(54 lesions)
2.77
[1.62 - 3.92]
< 0.0001 69 4.49
[3.16 - 5.82]
< 0.0001 82
Bone
(213 lesions)
2.73
[2.43 - 2.92]
< 0.0001 63 3.80
[3.45 - 4.14]
< 0.0001 69
Other
(10 lesions)
2.32
[−21.82 – 26.46]
0.437 78 2.73
[−21.54 – 27.00]
0.389 73
Fig. 2 Boxplots visualising the difference from 1h to 3h in SUVmean and cSUVmean for malignant lesions, according to different subgroups and
reference tissue. The difference between the two time-points were calculated as ΔSUV=SUV3h - SUV1h. Due to only one cerebral lesion, data are
not shown for this group
Baun et al. BMC Medical Imaging  (2018) 18:11 Page 6 of 10
could partly be due to the finding that 8 of the 21 lesions
(38%) in the group with local recurrence showed de-
creased SUV from 1h to 3h compared to only 10% in pa-
tients with distant recurrence. Suga et al. reported
similar results from 52 patients with suspected local re-
currence of breast cancer, where SUVmax increased in
84% of the lesions and decreased in 16% of the lesions
between 1h and 2h scans, while overall SUVmax in-
creased by 18% [35]. The higher increase in SUVmax in
our study could be due to the later imaging point at 3h.
Several studies have performed delayed or dual-time
imaging in breast cancer but have only shown a small
improvement in detecting local recurrence, despite an
increased tumour-to-background ratio [11, 12, 36, 37].
Distant metastases in lung, lymph node, liver and bone
all increased in SUVmax, SUVmean, and cSUVmean from
1h to 3h, and especially for lymph node metastases. These
findings are supported by the literature, where several pub-
lications have stated the increased FDG accumulation over
time in different malignant lesions [7, 16, 17, 35].
In our study, we used healthy liver tissue for reference
measurement, which has previously been demonstrated
useful by Chirindel et al. [38]. For bone metastases, we
found a significant increase for SUVmax, SUVmean, and
cSUVmean between 1h and 3h. These findings are sup-
ported by a study of bone metastases in breast cancer
patients from Tian et al. [39]. Other diagnostic studies of
bone metastases and FDG-PET/CT have found that FDG
has a high sensitivity for detecting osteolytic and mixed
bone lesions compared to osteoblastic lesions, which can
be false-negative due to low metabolic activity [40, 41].
SUV can be influenced by a range of physiological and
technical parameters, which should be taken in consider-
ation by quantitative image analysis, to minimize bias
[42–44]. SUVmax demonstrates a high inter-observer re-
producibility and is often used as a semi-quantitative
measure of FDG-uptake. However, SUVmax is more
sensitive to image noise, and has been shown to have a
lower inter-study repeatability than SUVmean [45, 46].
While SUVmean may be a more reliable measure in het-
erogeneous tumours, it can be observer-dependent due
to lesion delineation dependency with variability in mask
placement and sensitivity to PVE, especially in smaller
lesions [26, 27, 47].
Impact of PVC performed with ROVER software
PVC of SUVmean had as expected a significant impact
in our study, in both the overall lesion group and the
various subgroups. However, PVC increased the stand-
ard deviation of cSUVmean compared to uncorrected
SUVmean, probably due to incorrect lesion delineation
caused by segmentation challenges (Fig. 2). The highest
impact of PVC was seen for breast lesions which also
had the smallest MTV according to ROVER. Our results
agree with the literature, showing that partial volume ef-
fects influence measured uptake in all lesions, especially
those smaller or of a size close to the limited spatial
resolution of the PET scanner, for which it causes a sig-
nificant underestimation of lesion extent and activity
level [26, 27, 47].
Several studies have demonstrated observer-related vari-
ability associated with manual delineation of ROI, which
can be reduced by the use of automatic or semi-automatic
contour drawing [48–50]. Prevalently employed automatic
delineation methods employing different threshold and
cut-offs, however, are also known to be suboptimal in
many cases, leading to segmentation bias [20, 49]. We
used ROVER software for PVC, which has previously been
shown to be feasibly and clinically useful [31, 34]. ROVER
software included background subtraction for each lesion,
but despite this we discovered practical challenges due to
non-uniformity of lesions and background activity. We ex-
perienced against expectation a decrease in MTV defined
by ROVER from 1h to 3h, despite the general known ten-
dency of increased FDG accumulation over time in malig-
nant lesions. This issue was probably caused by crucial
segmentation challenges associated with the semi-
automatic lesion delineation. Thus, by visual inspection of
the automatic lesion delineation in our study, the lesion
ROI in the 1h image often included background voxels
and thereby overestimated lesion size, compared to the
same lesion in the 3h image, where the lesion delineation
appeared more well-defined (Fig. 3). This indicates that
the threshold-based segmentation in ROVER led to over-
estimated volumes of small lesions, particularly in the
early scan, where the lesion-to-background ratio was low,
and through that an underestimation of SUVmean. We
used a fixed 40% threshold setting to semi-automatically
delineate lesions. This approach was based on the current
use in the literature and similar to the threshold of 41%
recommended by updated European guidelines [48, 51]. A
more systematic search of other threshold levels or rather
alternative segmentation methods that can provide more
accurate lesion delineation could be beneficial [32, 42, 49],
but lies outside the scope of this article.
Strengths and limitations of the study
The main strengths of our study are its prospective design
and clinically representative patient group with newly
diagnosed recurrence – verified by biopsy in all patients –
and, hence, yet untreated metastases. The scanning proto-
col consisted of whole-body scans at both 1h and 3h
allowing us to compare SUV measurements over time in
all recurrent lesions. A major limitation was that histo-
logical proof was not available for all lesions due to ethical
and practical reasons, and therefore a composite reference
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standard was the best option. Another limitation was the
observed suboptimal segmentation with a fixed 40% of
maximum value threshold. Segmentation methods using
separate masks for 1h and 3h images in each patient were
associated with challenges such as spatial mismatch be-
tween 1h and 3h acquisitions. This could contribute to
segmentation variability and potentially incorrect com-
parison of quantitative results from the two time-points.
Being the outcome of a single institution study, the
generalizability of our results is uncertain.
The overall intention with this study was to consider
whether a 3h scan should replace the 1h standard im-
aging in patients with metastatic breast cancer. Although
we found an increased tumour-to-background ratio in
3h compared to 1h scans, this was not associated with
improved diagnostic accuracy on a per-patient level as
shown in our previous publication [33]. Furthermore, 3h
protocols cause challenges regarding planning, patient
discomfort and healthcare costs. Based on these experi-
ences, it may not be justified to replace the standard 1h
by a delayed imaging protocol.
Conclusion
SUVs of FDG increased significantly from 1h to 3h in
malignant lesions of recurrent breast cancer and in all
types of lesions, while reference measurements in
healthy liver tissue decreased. PVC increased these
values significantly as expected, especially in breast me-
tastases. However, the demonstrated modest quantitative
advances of 3h imaging can hardly justify delayed PET
imaging on a routine basis in this patient group.
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